Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

Letters17 July 2018Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune DiseaseNoha Abdel-Wahab, MD, PhD, Mohsin Shah, MD, Maria A. Lopez-Olivo, MD, PhD, and Maria E. Suarez-Almazor, MD, PhDNoha Abdel-Wahab, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, Mohsin Shah, MDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, Maria A. Lopez-Olivo, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, and Maria E. Suarez-Almazor, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0209 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Because our article was a systematic review of reported cases in the literature, we were limited by the quality of information available in the original articles. Insufficient reporting of certain data was acknowledged. As such, we did not report information on the extent of tumor mass at the time of adverse events. We have included only reports describing patients with an established diagnosis of autoimmune disease before initiation of checkpoint inhibitor (CPI) therapy for concomitant cancer. We based our determination on the reports of the authors of the original articles, and most of these autoimmune diseases—such as psoriasis, ...References1. Fam AG. Paraneoplastic rheumatic syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000;14:515-33. [PMID: 10985984] CrossrefMedlineGoogle Scholar2. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10:662-70. [PMID: 25136782] doi:10.1038/nrrheum.2014.138 CrossrefMedlineGoogle Scholar3. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-92. [PMID: 28068177] doi:10.1200/JCO.2015.66.1389 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2073. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUse of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Noha Abdel-Wahab , Mohsin Shah , Maria A. Lopez-Olivo , and Maria E. Suarez-Almazor Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Yasuo Oshima , Noboru Hagino , Masumi Hara , and Takashi Ohfuji Metrics Cited byManagement of Cancer-Associated MyositisTreatment of rheumatic adverse events of cancer immunotherapyRespiratory ComplicationsBone Marrow–Liver–Thymus ( BLT ) Humanized Mice as a Tool to Assess Checkpoint Inhibitor Adverse EventsImmune Checkpoint Blockade and Skin Toxicity PathogenesisPulmonary Complications of Lung Cancer TherapiesRheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer ImmunotherapyReal-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint InhibitorsImmune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and ManagementPyroptosis-Related Gene Signatures Can Robustly Diagnose Skin Cutaneous Melanoma and Predict the PrognosisCheckpoint inhibitor therapy for metastatic triple-negative breast cancerSafety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease A Cohort StudyMonique K. van der Kooij, MD, Karijn P.M. Suijkerbuijk, MD, PhD, Maureen J.B. Aarts, MD, PhD, Franchette W.P.J. van den Berkmortel, MD, PhD, Christian U. Blank, MD, PhD, Marye J. Boers-Sonderen, MD, PhD, Jesper van Breeschoten, MSc, Alfonsus J.M. van den Eertwegh, MD, PhD, Jan Willem B. de Groot, MD, PhD, John B.A.G. Haanen, MD, PhD, Geke A.P. Hospers, MD, PhD, Djura Piersma, MD, PhD, Rozemarijn S. van Rijn, MD, PhD, Albert J. ten Tije, MD, PhD, Astrid A.M. van der Veldt, MD, PhD, Gerard Vreugdenhil, MD, PhD, Michiel C.T. van Zeijl, MD, Michel W.J.M Wouters, MD, PhD, Olaf M. Dekkers, MD, PhD, and Ellen Kapiteijn, MD, PhDNeurological Complications of Targeted Therapies and Immunotherapies for CancerInternational Consensus Guidance for Management of Myasthenia GravisMarked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intakeSarcoidosisCheckpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicineIncidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysisMultinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicityStrategies for improving the management of immune-related adverse eventsLung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune DiseasesCutaneous immune-related adverse events to checkpoint inhibitorsImmune checkpoint inhibitor-induced inflammatory arthritis: identification and managementAutoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategyScleroderma-like syndrome associated with pembrolizumabCheckpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestationsA Review of Immune-Mediated Adverse Events in MelanomaAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillanceEndocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know) 17 July 2018Volume 169, Issue 2Page: 133-134KeywordsAdverse eventsAutoimmune diseasesCancer treatmentCorticosteroid therapyDisclosureResearch designSystematic reviewsThyroid diseasesToxicityUlcerative colitis ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...